康隆達(603665.SH):擬推不超1272萬股限制性股票和股票期權激勵計劃
格隆匯9月24日丨康隆達(603665.SH)2022年限制性股票和股票期權激勵計劃(草案),該激勵計劃採取的激勵工具為限制性股票和股票期權。股票來源為公司向激勵對象定向發行公司A股普通股。
該激勵計劃擬向激勵對象授予的權益總數不超過1272.00萬股,約佔該激勵計劃草案公吿時總公司股本的7.92%。其中首次授予權益1019.40萬股,預留授予權益252.60萬股。
該激勵計劃授予激勵對象限制性股票的授予價格為23.57元/股,授予激勵對象股票期權的行權價格(含預留授予)為35.35元/份。該激勵計劃首次授予的激勵對象共計116人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.